ArticleMMWR. Morbidity and mortality weekly report2021
Progress in Immunization Safety Monitoring - Worldwide, 2010-2019.
Article in MMWR. Morbidity and mortality weekly report, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- Establishing a Multicenter Active Adverse Events Following Immunization Sentinel Surveillance Network Across 22 Tertiary Care Hospitals in India: Protocol for a Prospective Observational Study.JMIR research protocols · 2025Article
- Geopharmacosurveillance of reporting rates of events supposedly attributable to vaccination or immunization against COVID-19.Revista latino-americana de enfermagem · 2025Article
- The association between routine immunisation and COVID-19 vaccination in small Island developing states.PloS one · 2025Article
- Immunization safety monitoring: addressing vaccine hesitancy and enhancing coverage in crisis-affected regions-insights from Lebanon, Ukraine, and Sudan.Therapeutic advances in vaccines and immunotherapy · 2025Review
- Landscape review of active vaccine safety surveillance activities for COVID-19 vaccines globally.Vaccine: X · 2024Article
- Collaboration within the global vaccine safety surveillance ecosystem during the COVID-19 pandemic: lessons learnt and key recommendations from the COVAX Vaccine Safety Working Group.BMJ global health · 2024Review
- [Experience of setting up a state pharmacovigilance committee during the COVID-19 pandemicExperiencia de la puesta en marcha de un comité estatal de farmacovigilancia durante la pandemia de COVID-19].Revista panamericana de salud publica = Pan American journal of public health · 2024Article
- Progress in Immunization Safety Monitoring - Worldwide, 2020-2022.MMWR. Morbidity and mortality weekly report · 2023Article
- Measuring National Immunization System Performance: A Systematic Assessment of Available Resources.Global health, science and practice · 2023Review
- Barriers to optimal AEFI surveillance and documentation in Nigeria: Findings from a qualitative survey.PLOS global public health · 2023Article
- Multi-dose vials versus single-dose vials for vaccination: perspectives from lower-middle income countries.Human vaccines & immunotherapeutics · 2022Article
- Commentary: Strategies to Address COVID-19 Vaccine Hesitancy and Mitigate Health Disparities in Minority Populations.Frontiers in public health · 2021Article
- Serious adverse event following immunization and thromboembolic events associated with COVID19 vaccination: An analysis of nationwide causality assessment from India.Indian heart journalArticle
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High levels of coverage with safe and effective immunizations are critical to the successful control and prevention of vaccine-preventable diseases worldwide. In addition to stringent standards to regulate the safety of vaccines, robust postlicensure monitoring systems help ensure that the benefits of vaccines continue to outweigh the risks for the populations who receive them. National Expanded Programmes on Immunization (EPI) are typically responsible for identifying and investigating adverse events following immunization (AEFI), including assessment of causality. National regulatory authorities (NRAs) are mandated to perform postlicensure surveillance of adverse drug reactions, including those associated with receipt of vaccines. This report describes global progress toward meeting World Health Organization (WHO) indicators on minimal country capacity for vaccine safety surveillance and coordination of AEFI reporting between countries' EPI and NRAs. In 2019, among 194 countries, 129 (66.5%) reported having an operational national AEFI causality review committee, compared with 94 (48.5%) in 2010. During 2010-2019, the proportion of countries reporting ≥10 AEFI per 100,000 surviving infants per year (an indicator of country capacity to monitor immunization safety) increased, from 41.2% to 56.2%. In 2019, however, only 46 (23.7%) countries reported AEFI data from both EPI and NRAs. Although global progress has been made toward strengthening systems for vaccine safety monitoring over the past decade, new indicators for monitoring global immunization safety performance are needed to better reflect program functionality. Continued global efforts will be vital to address barriers to routine reporting of AEFI, build national capacity for AEFI investigation and data management, and improve sharing of AEFI data at national, regional, and global levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.